Searched for
PLASMA BIOPHARMACEUTICAL
More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Being tactical not an option, but a necessity: Prescription for war and volatility; 7 pharma stocks with upside potential of up to 39%In times of major geopolitical conflicts, there is no point in looking at the day-to-day movement of the Nifty and Sensex. There are some s...
- Pharma stocks: Time to change the prescription? 13 pharma stocks with an upside potential of up to 39%Close to three decades back, when Indian pharma firms began to move into the US market, they faced many challenges. And the fact is that th...
- Eight Roads-backed PlasmaGen Biosciences raises Rs 150 crore at Rs 1,500 crore valuationPlasmaGen Biosciences has secured Rs 150 crore in a funding round led by ViNS Bioproducts, valuing the company at over Rs 1,500 crore. This...
- Sun Pharma appoints Kirti Ganorkar as MD; Dilip Shanghvi to continue as the Executive Chairman of the BoardSun Pharmaceutical Industries has appointed Kirti Ganorkar as Managing Director, succeeding Dilip Shanghvi, effective September 1. Shanghvi...
- MNC pharma: Time to relook at them? 8 pharma stocks, 4 with an upside potential of between 16 and 47%In the past four years, several MNC pharma companies announced the sale of a part of their businesses in India. Some of this was part of gl...
- India tackles snakebite crisis: New action plan aims to halve deaths by 2030Snakebites pose a significant threat in India, which has the highest snakebite mortality rate globally. A 2020 study reported 1.2 million d...
- For calibrating and diversifying risks? 6 midcap stocks from different sectors with the right financial matrixAs the Dalal street continues to be in party mode, staying bullish would appear to be the most logical thing at this point of time. Why fig...
- Footpath Ventures eyes stake in Rajasthan Royals; IT hiring picks upUS-based Footpath Ventures is in advanced talks to pick up a stake in Rajasthan Royals, a franchise in the Indian Premier League (IPL). Thi...
- PlasmaGen Biosciences raises Rs 225 crore in equity fundingThe Bengaluru-based startup will use the proceeds to boost growth of plasma products. It is also expected to use the corpus to expand its p...
- Australian shares rise as CSL boosts healthcare stocks"Health stocks are certainly on the consciousness of investors," said Brad Smoling, managing director of Smoling Stockbroking.
- DCGI nod to Phase-1 human trials of 'antisera' with potential to treat COVID-19Antisera are blood serum high in antibodies against specific antigens and are injected in humans to help kickstart the immune system to fig...
- ICMR, Biological E Ltd develop potential treatment for COVID-19The ICMR in collaboration with a Hyderabad-based biopharmaceutical company has developed "highly purified antisera" prepared by injecting i...
- Australia, NZ end firmer on optimism around Covid-19 treatment, US earningsNew Zealand's benchmark S&P/NZX 50 index rose 0.4% to 11,434.79.
- Advent to buy majority stake in Bharat SerumsUS-based private equity fund Advent International has signed a definitive agreement to acquire a majority stake in Bharat Serums and Vaccin...
- Carlyle-Zydus and Advent join race to acquire Bharat Serums and Vaccines LtdThey are up against domestic pharma companies Dr Reddy's Labs, Mankind & Goldman Sachs which have also made offers.
- Natco settles patent litigation with Celgene on cancer drugNatco and its US partner Allergan have settled a pending litigation with Celgene regarding generic Lenalidomide capsules used for treatment...
- Reliance Life Sciences bets big on biosimilarsReliance Life Sciences (RLS), a company promoted by Reliance Industries’ chairman, Mukesh Ambani, is looking at biopharmaceuticals as a hug...
- Reliance Life kicks off contract manufacturingMukesh Ambani’s dream project, Reliance Life Sciences (RLS) has started contract manufacturing and contract research of biopharmaceuticals ...
Load More
